Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1161/CIRCULATIONAHA.121.058103
- Subjects: HIPERTENSÃO; INSUFICIÊNCIA CARDÍACA; DIABETES MELLITUS; RESULTADO DE TRATAMENTO; FÁRMACOS (SISTEMA CARDIOVASCULAR)
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2022
- Source:
- Título do periódico: Circulation
- ISSN: 0009-7322
- Volume/Número/Paginação/Ano: v. 145, n. 21, p. 1581-1591, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
FURTADO, Remo H. M. et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.058103. Acesso em: 27 set. 2024. -
APA
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 145( 21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103 -
NLM
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 set. 27 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103 -
Vancouver
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 set. 27 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1161/CIRCULATIONAHA.121.058103 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
